The results of a collaborative study with Professor Hiroshi Handa of Tokyo Medical University and Professor Masahiro Kizaki of Saitama Medical University were published in Nature Chemical Biology on September 21. The study revealed that the degradation of a protein called ARID2 is involved in the anticancer effect of pomalidomide, a drug for multiple myeloma, and that ARID2 is useful as a marker of poor prognosis in relapsed/refractory multiple myeloma. ARID2 is a promising target for the diagnosis and treatment of relapsed/refractory multiple myeloma. For detail, please also see the press release below.